Merus Labs International Company Profile (NASDAQ:MSLI)

About Merus Labs International (NASDAQ:MSLI)

Merus Labs International logoMerus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MSLI
  • CUSIP: N/A
  • Web:
  • Market Cap: $139.66 million
  • Outstanding Shares: 117,355,000
Average Prices:
  • 50 Day Moving Avg: $0.93
  • 200 Day Moving Avg: $0.89
  • 52 Week Range: $0.70 - $1.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 59.51
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $76.47 million
  • Price / Sales: 1.83
  • Book Value: $1.17 per share
  • Price / Book: 1.01
  • EBIDTA: $30.45 million
  • Net Margins: -10.36%
  • Return on Equity: -3.94%
  • Return on Assets: -2.20%
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 0.77%
  • Quick Ratio: 0.55%
  • Average Volume: 95,033 shs.
  • Beta: 1.77
  • Short Ratio: 60.94

Frequently Asked Questions for Merus Labs International (NASDAQ:MSLI)

What is Merus Labs International's stock symbol?

Merus Labs International trades on the NASDAQ under the ticker symbol "MSLI."

How were Merus Labs International's earnings last quarter?

Merus Labs International Inc (NASDAQ:MSLI) posted its quarterly earnings data on Monday, August, 10th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.03. The company had revenue of $7.73 million for the quarter, compared to analyst estimates of $17.19 million. Merus Labs International had a negative net margin of 10.36% and a negative return on equity of 3.94%. View Merus Labs International's Earnings History.

Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?

8 brokers have issued twelve-month target prices for Merus Labs International's shares. Their forecasts range from $1.00 to $14.00. On average, they expect Merus Labs International's share price to reach $3.88 in the next twelve months. View Analyst Ratings for Merus Labs International.

What are analysts saying about Merus Labs International stock?

Here are some recent quotes from research analysts about Merus Labs International stock:

  • 1. According to Zacks Investment Research, "Merus Labs International Inc. is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The Company's products include anti-infectives and wound care products. Merus Labs International Inc., formerly known as Envoy Capital Group Inc., is based in Vancouver, Canada. " (4/18/2017)
  • 2. Canaccord Genuity analysts commented, "We look at MCRB as the leader in advancing the microbiome approach to treating chronic diseases and infections. While we acknowledge that the near-term focus of investors may be how the primary endpoint of reducing the relative risk of infection recurrence in the SER-109 Phase II ECOSPOR clinical study in recurrent Clostridium difficile infection (CDI) was not achieved, we think the stock sell-off since July 29 is overdone. The development of MCRB’s other clinical-stage assets are partnered with Swiss-based Nestle, which has agreed to fund up to one-third of development costs, according to a $1.9B agreement signed in January 2016. MCRB has also signed four other collaborations, which we think represent nascent upside potential in the stock." (8/12/2016)

Who are some of Merus Labs International's key competitors?

Who are Merus Labs International's key executives?

Merus Labs International's management team includes the folowing people:

  • Michael S. Cloutier, Independent Chairman of the Board
  • Barry Fishman, Chief Executive Officer, Director
  • Michael Bumby, Chief Financial Officer
  • Robert McLay, Vice President - Sales and Marketing
  • Frank Rotmann, Vice President and Head of European Operations
  • Robert Bloch M.D., Director
  • Theresa Sheila Firestone, Independent Director
  • David D. Guebert CPA, Independent Director
  • Robert S. Pollock, Independent Director
  • Timothy G. Sorensen, Independent Director

Who owns Merus Labs International stock?

Merus Labs International's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (3.78%), TD Asset Management Inc. (0.25%) and K.J. Harrison & Partners Inc (0.17%). View Institutional Ownership Trends for Merus Labs International.

Who bought Merus Labs International stock? Who is buying Merus Labs International stock?

Merus Labs International's stock was bought by a variety of institutional investors in the last quarter, including K.J. Harrison & Partners Inc, Acadian Asset Management LLC and TD Asset Management Inc.. View Insider Buying and Selling for Merus Labs International.

How do I buy Merus Labs International stock?

Shares of Merus Labs International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merus Labs International's stock price today?

One share of Merus Labs International stock can currently be purchased for approximately $1.19.

MarketBeat Community Rating for Merus Labs International (NASDAQ MSLI)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Merus Labs International (NASDAQ:MSLI) (?)
Ratings Breakdown: 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $3.88 (226.02% upside)

Analysts' Ratings History for Merus Labs International (NASDAQ:MSLI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Canaccord GenuityDowngradeHold$1.65LowView Rating Details
2/13/2017Bloom BurtonReiterated RatingHoldN/AView Rating Details
12/16/2016ScotiabankReiterated RatingSector Perform$1.75 -> $1.25N/AView Rating Details
12/16/2016Paradigm CapitalReiterated RatingHold$1.60 -> $1.00N/AView Rating Details
12/15/2016CIBCReiterated RatingOutperform -> Neutral$2.40 -> $1.50N/AView Rating Details
11/8/2016Citigroup IncReiterated RatingNeutralN/AView Rating Details
6/13/2016WedbushReiterated RatingOutperformN/AView Rating Details
6/13/2016GuggenheimReiterated RatingBuyN/AView Rating Details
2/5/2016MackieReiterated RatingHold$1.90 -> $2.30N/AView Rating Details
2/5/2016Dundee SecuritiesReiterated RatingBuy$3.50 -> $3.60N/AView Rating Details
11/30/2015Royal Bank of CanadaReiterated RatingSector Outperform$2.90N/AView Rating Details
5/29/2015TD SecuritiesInitiated CoverageBuyN/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Merus Labs International (NASDAQ:MSLI)
Earnings by Quarter for Merus Labs International (NASDAQ:MSLI)
Earnings History by Quarter for Merus Labs International (NASDAQ:MSLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q117($0.02)($0.04)$23.18 million$19.53 millionViewListenView Earnings Details
8/10/2015Q3 2015$0.02($0.01)$17.19 million$7.73 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merus Labs International (NASDAQ:MSLI)
2017 EPS Consensus Estimate: ($0.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.01)($0.01)($0.01)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171$0.00$0.00$0.00
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)


Dividend History for Merus Labs International (NASDAQ:MSLI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merus Labs International (NASDAQ:MSLI)
No insider trades for this company have been tracked by


Headline Trends for Merus Labs International (NASDAQ:MSLI)
Latest Headlines for Merus Labs International (NASDAQ:MSLI)
DateHeadline logoMerus Labs International, Inc. :MSLI-US: Earnings Analysis: Q2, 2017 By the Numbers : May 26, 2017 - May 26 at 7:35 PM logoMerus Labs International Inc (MSLI) Receives Average Rating of "Hold" from Brokerages - May 19 at 2:02 PM logoMerus Labs International Inc Forecasted to Earn FY2018 Earnings of $0.02 Per Share (MSLI) - May 15 at 9:50 AM logoCormark Comments on Merus Labs International Inc's Q4 2017 Earnings (MSLI) - May 12 at 3:26 PM logoMerus Labs (MSLI) to be Acquired by Norgine B.V. for $1.65/Share - May 12 at 12:12 AM logoMerus Labs Shares Spike 50% on Acquisition - May 11 at 7:09 PM logoMerus Labs International Inc (MSLI) Lowered to Hold at Canaccord Genuity - May 11 at 4:20 PM logoMerus Labs Announces Key Milestone for Sintrom® Profit Enhancing Initiative - May 4 at 6:44 PM logoMerus Labs International (MSLI) Given Media Sentiment Score of 0.46 - May 3 at 4:16 PM logoMerus Labs International (MSLI) Earns Daily News Sentiment Rating of 0.21 - April 29 at 4:18 PM logoMerus Labs International (MSLI) Given Daily Media Sentiment Rating of 0.13 - April 25 at 9:40 PM logoMerus Labs International Inc (MSLI) Given Consensus Rating of "Hold" by Brokerages - April 24 at 1:54 PM logoMerus Labs International (MSLI) Receiving Very Favorable Press Coverage, Report Shows - April 21 at 8:45 AM logoMerus Labs International (MSLI) Receiving Somewhat Favorable News Coverage, AlphaOne Reports - April 18 at 6:49 PM logoMerus Labs International (MSLI) Getting Positive Press Coverage, AlphaOne Reports - April 15 at 2:55 PM logoMerus Labs International Inc (MSLI) Sees Large Increase in Short Interest - April 14 at 9:40 AM logoMerus Labs International Inc (MSLI) Receives Consensus Rating of "Hold" from Analysts - March 28 at 1:46 PM logoCanaccord Genuity Analysts Give Merus Labs International Inc (MSLI) a $3.00 Price Target - March 26 at 11:04 PM logoBRIEF-Merus Labs announces changes to stock option plan to address ISS recommendation - March 13 at 10:14 AM logo3:28 am Merus Labs responds to media reports suggesting co is exploring strategic alternatives; confirms using Rothschild & Co to evaluate options - March 1 at 6:45 PM logoMerus Labs International's (MSLI) CEO Barry Fishman on Q1 2017 Results - Earnings Call Transcript - February 14 at 8:44 PM logoWhat Makes Merus Labs (MSLI) a Strong Sell? - January 9 at 7:23 PM logoMerus Labs slumps 15% on fiscal year-end and Q4 results; modest growth in non-GAAP earnings expected - December 15 at 12:22 AM logoMerus Labs Reports Fiscal Q4 and 2016 Results - December 14 at 7:21 PM logoBarry Fishman Joins Aurora Board as Independent Director - October 12 at 11:35 AM logoMerus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings Release - August 10 at 6:43 PM logoMerus Announces Reduced Leverage and Provides Business Update - July 4 at 7:00 AM logoMerus Labs Appoints Two New Senior Executives - June 30 at 4:00 PM logoMerus Labs International Inc. Announces Deemed Exercise of Special Warrants - May 18 at 4:24 PM logoMerus Labs Reports Fiscal Q2 2016 Results - May 11 at 4:00 PM logoMerus Labs Int'l (MSLI) to Acquire Three Cardiovascular Products from UCB in EUR 92M Deal - February 2 at 2:12 PM logo2:55 pm Merus Labs to acquire UCB's rights to Elantan, Isoket and Deponit in Europe and select other markets for EUR92 mln; updates FY16 EBITDA guidance (shares halted) - February 1 at 2:55 PM logoMERUS LABS INTERNATIONAL INC. Financials - January 5 at 1:04 PM logoMerus Labs Announces Filing of Preliminary Base Shelf Prospectus - July 10 at 7:00 AM logoMerus Labs Provides an Update on German Reimbursement Review - June 3 at 4:00 PM



Merus Labs International (MSLI) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff